Results 191 to 200 of about 26,593 (244)

Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands. [PDF]

Pharmaceuticals (Basel)
de Roode KE, Joosten L, Behe M.
europepmc   +1 more source

Autophagy inhibition improves the targeted radionuclide therapy efficacy of ¹³¹I-FAP-2286 in pancreatic cancer xenografts. [PDF]

J Transl Med
Liu X, Li D, Ma T, Luo X, Peng Y, Wang T, Zuo C, Cai J.   +7 more
europepmc   +1 more source

Use of radioactive ion beams for bio-medical research [PDF]

, 1997
Allen, B, Beyer, G, Buchegger, F, Donath, A, Mäcke, H, Offord, R E, Senekowitsch-Schmidtke, R, Slosmann, D, Stöcklin, G, Terrier, F   +9 more
core  

Prospective phase II trial of [⁶⁸Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy. [PDF]

EJNMMI Res
Azam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I, Skjøth-Rasmussen J, Kjaer A.   +7 more
europepmc   +1 more source

Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy. [PDF]

Front Immunol
Adhikarla V, Awuah D, Caserta E, Minnix M, Kuznetsov M, Krishnan A, Wong JYC, Shively JE, Wang X, Pichiorri F, Rockne RC.   +10 more
europepmc   +1 more source

A Monte Carlo study comparing dead-time losses of a gamma camera between tungsten functional paper and lead sheet for dosimetry in targeted radionuclide therapy with Lu-177. [PDF]

Ann Nucl Med
Nakanishi K, Fujita N, Iwanaga H, Asano Y, Abe S, Nishii R, Kato K.   +6 more
europepmc   +1 more source

Cysteine-selective [¹⁸⁸Re]Re(v) radiolabelling of a Nanobody® for targeted radionuclide therapy using a "chelate-then-click" approach. [PDF]

Chem Sci
Melis DR, Segers C, Wellens J, Van de Voorde M, Blacque O, Ooms M, Gasser G, Opsomer T.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunomodulatory effects of targeted radionuclide therapy

2023
It is now clear that conventional radiation therapy can reinstate cell death immunogenicity. Recent preclinical data indicate that targeted radionuclide therapy that irradiate tumors at continuous low dose rate also can elicit immunostimulatory effects and represents a promising strategy to circumvent immune checkpoint inhibitor resistance.
Constanzo, J., Bouden, Y., Godry, L., Kotzki, P.-O., Deshayes, E., Pouget, J.-P.   +5 more
openaire   +2 more sources

Targeted Radionuclide Therapy of Melanoma

Seminars in Nuclear Medicine, 2016
An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic
Abdullah, Norain, Ekaterina, Dadachova
openaire   +2 more sources